

June 14, 2019

## Aster DM Healthcare (Trivandrum) Private Limited: Ratings withdrawn

### Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term Term Loan	300.00	300.00	[ICRA]BBB+ (SO)(Positive); Withdrawn
<b>Total</b>	<b>300.00</b>	<b>300.00</b>	

\*Instrument details are provided in Annexure-1

### Rationale

The afore-mentioned ratings assigned to Rs. 300.0-crore fund-based facility of Aster DM Healthcare (Trivandrum) Private Limited (ADHPL) have been withdrawn at the request of the company and upon receipt of no dues certificate from the bankers, in accordance with ICRA's policy on withdrawal and suspension of credit rating.

### Outlook: Not Applicable

### Key rating drivers

Not Applicable

### Liquidity Position:

Not applicable

### Analytical approach:

Analytical Approach	Comments
Applicable Rating Methodologies	<a href="#">Corporate Credit Rating Methodology</a> <a href="#">Rating Methodology for Hospitals</a> <a href="#">ICRA's Policy on Withdrawal and Suspension of Credit Rating</a>
Parent/Group Support	Not Applicable
Consolidation / Standalone	Not Applicable

### About the company

ADHTPL was incorporated on February 25, 2010 as a private limited company under the name DM Eye Care (Delhi) Private Limited. The name of the company was subsequently changed to Aster DM Healthcare (Trivandrum) Private Limited on May 30, 2016. ADHL holds 99.99% of the issued and paid up share capital of ADHTPL. Dr. Azad Moopen holds one equity share aggregating to 0.01% of the share capital of ADHTPL beneficially in favour of ADHL. The company has acquired land in Trivandrum, Kerala for Greenfield expansion for the construction of Multispecialty hospital in two phases (Phase I with 510 beds and Phase II with 239 beds) to be commissioned by FY2022.

## About the guarantor

Aster DM Healthcare Limited (ADHL / the company - formerly, DM Healthcare Pvt Ltd), established in 1987, is the holding company of the Aster Group, which provides healthcare services through hospitals, clinics and pharmacies. Following a reorganisation of its structure in 2008, the Group's operations across the GCC countries and India were consolidated under ADHL. As on March 31, 2019, the company had 9 subsidiaries, 48 stepdown subsidiaries and 4 associate companies, through which the Aster Group operates 24 hospitals, 114 clinics, and 219 pharmacies in the GCC region and India (as on March 31, 2019). The Group is promoted by Dr. Azad Moopen and his family. It operates its services under the Medcare, Aster and Access brands. The GCC region accounted for 85% of the consolidated revenues in FY2019, with the remaining coming from India. ADHL was listed on the India stock exchanges on February 26, 2018.

The Group reported a net profit of Rs. 368 crore on an operating income of Rs. 7963 crore in FY2019 as compared to a net profit of Rs. 290 crore on an operating income of Rs. 6721 crore in FY2018.

## Key financial indicators

	FY2017	FY2018
Operating Income (Rs. crore)	0.00	0.00
PAT (Rs. crore)	-0.34	-0.22
OPBDIT/OI (%)	n.m.	n.m.
RoCE (%)	n.m.	n.m.
Total Debt/TNW (times)	-13.66	-13.66
Total Debt/OPBDIT (times)	n.m.	n.m.
Interest coverage (times)	n.m.	n.m.

## ADHL's key financial indicators (consolidated)

	FY2018 Audited	FY2019 Provisional
Operating Income (Rs. crore)	6,721	7,963
PAT (Rs. crore)	290	368
OPBDIT/OI (%)	9.1%	10.8%
RoCE (%)	10.1%	10.5%
Total Debt/TNW (times)	0.74	0.76
Total Debt/OPBDIT (times)	3.86	3.23
Interest coverage (times)	4.32	5.00

**Status of non-cooperation with previous CRA: Not applicable**

**Any other information: None**

## Rating history for last three years

Instrument		Current Rating (FY2020)			Chronology of Rating History for the past 3 years			
		Type	Amount Rated (Rs. crore)	Amount Outstanding (Rs Crore) <sup>##</sup>	Date & Rating	Date & Rating in FY2019	Date & Rating in FY2018	Date & Rating in FY2017
					June 2019	August 2018	NA	NA
1	Long-term Term Loan	Long Term	300.00	-	[ICRA]BBB+ (SO)(Positive); Withdrawn	[ICRA]BBB+ (SO)(Positive); Assigned	-	-

<sup>##</sup>As on March 31, 2019

## Complexity level of the rated instrument:

ICRA has classified various instruments based on their complexity as "Simple", "Complex" and "Highly Complex". The classification of instruments according to their complexity levels is available on the website [www.icra.in](http://www.icra.in)

## Annexure-1: Instrument Details

ISIN No	Instrument Name	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Term Loan	August 2016	-	August 2032	300.00	[ICRA]BBB+ (SO)(Positive); Withdrawn

Source: Aster DM Healthcare (Trivandrum) Private Limited

## ANALYST CONTACTS

**Shubham Jain**

+91 124 4545 306

[shubhamj@icraindia.com](mailto:shubhamj@icraindia.com)

**Mathew Kurian Eranat**

+91 80 4332 6415

[mathew.eranat@icraindia.com](mailto:mathew.eranat@icraindia.com)

**Ishan Luthra**

+91 80 4332 6426

[ishan.luthra@icraindia.com](mailto:ishan.luthra@icraindia.com)

## RELATIONSHIP CONTACT

**Jayanta Chatterjee**

+91 80 4332 6401

[jayantac@icraindia.com](mailto:jayantac@icraindia.com)

## MEDIA AND PUBLIC RELATIONS CONTACT

**Ms. Naznin Prodhani**

Tel: +91 124 4545 860

[communications@icraindia.com](mailto:communications@icraindia.com)

## Helpline for business queries:

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

[info@icraindia.com](mailto:info@icraindia.com)

## About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

## ICRA Limited

### Corporate Office

Building No. 8, 2nd Floor, Tower A; DLF Cyber City, Phase II; Gurgaon 122 002

Tel: +91 124 4545300

Email: [info@icraindia.com](mailto:info@icraindia.com)

Website: [www.icra.in](http://www.icra.in)

### Registered Office

1105, Kailash Building, 11th Floor; 26 Kasturba Gandhi Marg; New Delhi 110001

Tel: +91 11 23357940-50

### Branches

Mumbai + (91 22) 24331046/53/62/74/86/87

Chennai + (91 44) 2434 0043/9659/8080, 2433 0724/ 3293/3294,

Kolkata + (91 33) 2287 8839 /2287 6617/ 2283 1411/ 2280 0008,

Bangalore + (91 80) 2559 7401/4049

Ahmedabad+ (91 79) 2658 4924/5049/2008

Hyderabad + (91 40) 2373 5061/7251

Pune + (91 20) 2556 0194/ 6606 9999

© Copyright, 2019 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents